

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8268143

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS AG	09/29/2023
RECEIVING PARTY DATA	
Name:	BAUSCH + LOMB IRELAND LIMITED
Street Address:	3013 LAKE DRIVE
Internal Address:	CITYWEST BUSINESS CAMPUS
City:	DUBLIN
State/Country:	IRELAND
Postal Code:	24
PROPERTY NUMBERS Total: 52	
Property Type	Number
Application Number:	16444894
Application Number:	16444897
Application Number:	16444904
Application Number:	16444912
Application Number:	17069404
Application Number:	62656552
Application Number:	17670215
Application Number:	16463137
Application Number:	62596668
Application Number:	62613908
Application Number:	16852123
Application Number:	14992975
Application Number:	62125073
Application Number:	16805188
Application Number:	15094849
Application Number:	62178464
Application Number:	17147196
Application Number:	15874377
Application Number:	62448791

Property Type	Number
Application Number:	62492624
Application Number:	16972085
Application Number:	62693818
Application Number:	62653446
Application Number:	62520270
Application Number:	62523071
Application Number:	18311673
Application Number:	16811879
Application Number:	62814773
Application Number:	62534083
Application Number:	62814764
Application Number:	17127584
Application Number:	62951903
Application Number:	63049582
Application Number:	62913498
Application Number:	17096348
Application Number:	62934225
Application Number:	63011800
Application Number:	63049110
Application Number:	17509383
Application Number:	17692991
Application Number:	17233105
Application Number:	63011808
Application Number:	17233135
Application Number:	63166754
Application Number:	63159830
Application Number:	63212545
Application Number:	63323859
Application Number:	63337372
Application Number:	63317381
Application Number:	63321028
Application Number:	63501790
Application Number:	18488723

CORRESPONDENCE DATA

Fax Number: (617)310-6001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6173106000

Email: bosipmail@gtlaw.com
Correspondent Name: CHINH H. PHAM
Address Line 1: C/O GREENBERG TRAURIG, LLP
Address Line 2: ONE INTERNATIONAL PLACE, SUITE 2000
Address Line 4: BOSTON, MASSACHUSETTS 02110

NAME OF SUBMITTER: CHINH H. PHAM

SIGNATURE: /Chinh H. Pham, Reg. No. 39,329/

DATE SIGNED: 11/09/2023

Total Attachments: 53

source=Assignment_Novartis_BL#page1.tif
source=Assignment_Novartis_BL#page2.tif
source=Assignment_Novartis_BL#page3.tif
source=Assignment_Novartis_BL#page4.tif
source=Assignment_Novartis_BL#page5.tif
source=Assignment_Novartis_BL#page6.tif
source=Assignment_Novartis_BL#page7.tif
source=Assignment_Novartis_BL#page8.tif
source=Assignment_Novartis_BL#page9.tif
source=Assignment_Novartis_BL#page10.tif
source=Assignment_Novartis_BL#page11.tif
source=Assignment_Novartis_BL#page12.tif
source=Assignment_Novartis_BL#page13.tif
source=Assignment_Novartis_BL#page14.tif
source=Assignment_Novartis_BL#page15.tif
source=Assignment_Novartis_BL#page16.tif
source=Assignment_Novartis_BL#page17.tif
source=Assignment_Novartis_BL#page18.tif
source=Assignment_Novartis_BL#page19.tif
source=Assignment_Novartis_BL#page20.tif
source=Assignment_Novartis_BL#page21.tif
source=Assignment_Novartis_BL#page22.tif
source=Assignment_Novartis_BL#page23.tif
source=Assignment_Novartis_BL#page24.tif
source=Assignment_Novartis_BL#page25.tif
source=Assignment_Novartis_BL#page26.tif
source=Assignment_Novartis_BL#page27.tif
source=Assignment_Novartis_BL#page28.tif
source=Assignment_Novartis_BL#page29.tif
source=Assignment_Novartis_BL#page30.tif
source=Assignment_Novartis_BL#page31.tif
source=Assignment_Novartis_BL#page32.tif
source=Assignment_Novartis_BL#page33.tif
source=Assignment_Novartis_BL#page34.tif
source=Assignment_Novartis_BL#page35.tif
source=Assignment_Novartis_BL#page36.tif
source=Assignment_Novartis_BL#page37.tif

source=Assignment_Novartis_BL#page38.tif
source=Assignment_Novartis_BL#page39.tif
source=Assignment_Novartis_BL#page40.tif
source=Assignment_Novartis_BL#page41.tif
source=Assignment_Novartis_BL#page42.tif
source=Assignment_Novartis_BL#page43.tif
source=Assignment_Novartis_BL#page44.tif
source=Assignment_Novartis_BL#page45.tif
source=Assignment_Novartis_BL#page46.tif
source=Assignment_Novartis_BL#page47.tif
source=Assignment_Novartis_BL#page48.tif
source=Assignment_Novartis_BL#page49.tif
source=Assignment_Novartis_BL#page50.tif
source=Assignment_Novartis_BL#page51.tif
source=Assignment_Novartis_BL#page52.tif
source=Assignment_Novartis_BL#page53.tif

PATENT ASSIGNMENT AGREEMENT

This Patent Assignment Agreement (this “**Assignment**”), dated as of September 29, 2023 (the “**Effective Date**”), is entered into by and among Novartis AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland (“**Novartis AG**”), Novartis Pharmaceuticals Corporation, a company incorporated in Delaware whose address is 59 Route 10, East Hanover, NJ 07936 (“**Novartis Pharmaceuticals**” and together with Novartis AG, “**Assignors**” and each individually an “**Assignor**”), and Bausch + Lomb Ireland Limited, a private company limited by shares under the laws of the Republic of Ireland whose address is Citywest Business Campus, 3013 Lake Drive, Dublin, Ireland 24 (“**Assignee**”). Assignors and Assignee may be referred to herein individually as a “**Party**” and collectively as the “**Parties**”.

Capitalized terms used but not defined in this Assignment shall have the respective meanings ascribed to them in that certain Stock and Asset Purchase Agreement, by and among Novartis Pharma AG, a company incorporated in Switzerland (“**Swiss Seller**”), Novartis Finance Corporation, a company incorporated in New York (“**US Seller**”), and Assignee, dated as of June 30, 2023 (the “**Purchase Agreement**”).

WITNESSETH:

WHEREAS, pursuant to the terms and subject to the conditions of the Purchase Agreement, Swiss Seller and US Seller have agreed to cause Assignors to sell and assign to Assignee all of its rights, title and interest in, and Assignee has agreed to purchase and assume, among other things, the Purchased Patents (other than the transfer of Purchased Patents held by the Purchased Subsidiary, which shall be effected indirectly through the transfer of the Purchased Shares) (such Purchased Patents, other than those owned or held by the Purchased Subsidiary, including those set forth on Schedule A, the “**Assigned Patents**”), which are owned by and registered to the Assignors; and

WHEREAS, in connection with the transactions contemplated by the Purchase Agreement, each Assignor desires to assign to Assignee, and Assignee desires to acquire from each Assignor, all of such Assignor’s rights, title and interests in, to and under the Assigned Patents.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement, the Parties, intending to be legally bound, hereby agree as follows:

1. Each Assignor hereby sells, transfers, conveys, assigns and delivers to Assignee, all of such Assignor’s rights, title and interests in, to and under, arising in any jurisdiction throughout the world: (i) the Assigned Patents, and any and all patents and patent applications claiming priority from any Assigned Patent, in each case to be held and enjoyed by Assignee for its own use and enjoyment as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made, (ii) any and all royalties, fees, income, payments and other proceeds now or hereafter due or payable with respect to any of the Assigned Patents, (iii) all rights to sue, claim and recover, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief, for past,


present and future infringement or other violation of any Assigned Patents, and to collect, or otherwise recover, any such damages, and (iv) all rights to claim priority, file foreign counterparts, make applications for reissue and reexamination and all other similar legal protections with respect to the Assigned Patents.

2. This Assignment is governed by the terms and conditions of the Purchase Agreement. The delivery of this Assignment shall not amend, affect, enlarge, diminish, supersede, modify, replace, rescind, waive or otherwise impair any of the representations, warranties, covenants, terms or provisions of the Purchase Agreement or any of the rights, remedies or obligations of US Seller, Swiss Seller or Assignee provided for therein or arising therefrom in any way, all of which shall remain in full force and effect in accordance with their terms. The representations, warranties, covenants, terms and provisions contained in the Purchase Agreement shall not be merged with or into this Assignment but shall survive the execution and delivery of this Assignment to the extent, and in the manner, set forth in the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms of this Assignment, the terms of the Purchase Agreement shall control.
3. Promptly (and in any event within six months) following the Effective Date, subject to Assignor's prompt compliance with this Section 3, Assignee shall file this Assignment or such confirmatory assignment and other accompanying documents as may be required to record with the relevant patent offices the assignment of each Assigned Patent to Assignee. Each Assignor agrees to sign all necessary papers and do all lawful acts reasonably required to give effect to and record the assignment to Assignee under this Assignment, with Assignee bearing all out-of-pocket costs and expenses associated therewith.
4. This Assignment will be governed by, and enforced and construed in accordance with, the Law of the State of Delaware, including its statute of limitations, without regard to the conflict of Laws rules of such state that would result in the application of the Laws of another jurisdiction. This Assignment will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and permitted assigns. No waiver, modification or amendment of any provision of this Assignment shall be effective unless set forth in a written instrument executed by or on behalf of the Party against whom such claimed waiver, modification or amendment is sought to be enforced.
5. This Assignment may be executed in any number of counterparts and manually or electronically, and each such counterpart hereof shall be deemed to be an original, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Assignment by electronic mail or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Assignment.


[The remainder of this page has been intentionally left blank; Signature page follows.]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be duly executed by their respective authorized officers as of the Effective Date.


NOVARTIS AG

By: 
Printed Name: Isabelle Andrea Schubert Santana
Authorized Signatory


On this 29th day of September, 2023, before me personally, **Isabelle Andrea Schubert Santana**, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he or she executed the same in his or her authorized capacity, and that by his or her signature on the instrument the person, or the entity upon behalf of which the person acted, executed this instrument.


Notary Public

Andrea Schmutz
Notarin

By: 
Printed Name: Robert Carroll Stanley
Authorized Signatory

On this 29th day of September, 2023, before me personally, **Robert Carroll Stanley**, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he or she executed the same in his or her authorized capacity, and that by his or her signature on the instrument the person, or the entity upon behalf of which the person acted, executed this instrument.


Notary Public

[Signature Page to Patent Assignment Agreement]

Reg. 2023/ no. 195

PATENT
REEL: 065531 FRAME: 0589

APOSTILLE

(Convention de la Haye du 5 octobre 1961)

1. Country Swiss Confederation, Canton of Basel-City
Land Schweizerische Eidgenossenschaft, Kanton Basel-Stadt

This public document
Diese öffentliche Urkunde

2. has been signed by lic. iur. Andrea Schmutz
ist unterschrieben von
3. acting in the capacity of Notary Public
in seiner Eigenschaft als
4. bears the stamp/seal of Schmutz Andrea
Sie ist versehen mit dem
Stempel/Siegel des/der

Certified / Bestätigt


5. at / in Basel 6. the / am 29.09.2023

7. by the Legalisation Office of the Canton of Basel-City
durch das Beglaubigungsbüro des Kantons Basel-Stadt

8. No. / Nr. 261584 tax / Taxe CHF 20.00

9. stamp/seal
Stempel/Siegel

10. Signature Fabio Marzo
Unterschrift



PATENT

REEL: 065531 FRAME: 0590

IN WITNESS WHEREOF, the Parties have caused this Assignment to be duly executed by their respective authorized officers as of the Effective Date.

NOVARTIS PHARMACEUTICALS CORPORATION

By: *Robert M. Gleeson*
Printed Name: Robert M. Gleeson
Authorized Signatory

On this 29th day of Sept, 2023, before me personally, Robert M. Gleeson, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he or she executed the same in his or her authorized capacity, and that by his or her signature on the instrument the person, or the entity upon behalf of which the person acted, executed this instrument.

Lila E. Freeman
Notary Public

LILA E FREEMAN
Notary Public
State of New Jersey
My Commission Expires November 8, 2023
No. 50093703

IN WITNESS WHEREOF, the Parties have caused this Assignment to be duly executed by their respective authorized officers as of the Effective Date.


BAUSCH + LOMB IRELAND LIMITED

By: Breda Furlong
Printed Name: Breda Furlong
Authorized Signatory

On this 29 day of Sept, 2023, before me personally, Breda Furlong, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he or she executed the same in his or her authorized capacity, and that by his or her signature on the instrument the person, or the entity upon behalf of which the person acted, executed this instrument.

Colin Byrne
Notary Public

Colin Byrne
Notary Public
Dublin, Ireland
Commissioned For Life



[Signature Page to Patent Assignment Agreement]

ASSIGNED PATENTS

Schedule A

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
Topical Ocular Delivery Methods and Methods for Use in the Same	United States Of America	18 Jun 2019	16/444894	2019-0314195		Novartis AG
Topical Ocular Delivery Methods and Methods for Use in the Same	United States Of America	18 Jun 2019	16/444897	2019-0314196		Novartis AG
Topical Ocular Delivery Methods and Methods for Use in the Same	United States Of America	18 Aug 2019	16/444904	2019-0314197		Novartis AG
Topical Ocular Delivery Methods and Methods for Use in the Same	United States Of America	18 Jun 2019	16/444912	2019-0314198		Novartis AG
	United States Of America	13 Oct 2020	17/069404			Novartis AG
Topical Ocular Delivery Methods and Methods for Use in the Same	United States Of America	12 Apr 2018	62/656552			Novartis AG

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
	United States Of America	11 Feb 2022	17/670215			Novartis AG
Fluid Delivery Alignment System	United States Of America	07 Dec 2018	16/463137		11278448	Novartis AG
Fluid Delivery Alignment System	United States Of America	08 Dec 2017	62/596668			Novartis AG
Fluid Delivery System	United States Of America	05 Jan 2018	62/613908			Novartis AG

PATENT

REEL: 065531 FRAME: 0614

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
	United States Of America	17 Apr 2020	16/852123	2020-0246182		Novartis AG
	United States Of America	11 Jan 2016	14/992975		10624781	Novartis AG
Micro-Droplet Delivery Device And Methods	United States Of America	12 Jan 2015	62/125073			Novartis AG

PATENT

REEL: 065531 FRAME: 0615

	United States Of America	28 Feb 2020	16/805188			Novartis AG
Piezoelectric Dispenser With Replaceable Ampoule	United States Of America	08 Apr 2016	15/094849		10583038	Novartis AG
Piezoelectric Dispenser With Replaceable Ampoule	United States Of America	10 Apr 2015	62/178464			Novartis AG

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						
Piezoelectric Dispenser With Replaceable Ampoule	United States Of America	12 Jan 2021	17/147196			Novartis AG
Piezoelectric Dispenser With Replaceable Ampoule	United States Of America	18 Jan 2018	15/874377		10888454	Novartis AG
Piezoelectric Dispenser With Replaceable Ampoule	United States Of America	20 Jan 2017	62/448791			Novartis AG
[REDACTED]						
Piezoelectric Clamping Dispenser With Replaceable Ampoule	United States Of America	01 May 2017	62/492624			Novartis AG
[REDACTED]						

PATENT

REEL: 065531 FRAME: 0616

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
Topical Ocular Delivery Devices And Methods For Using The Same	United States Of America	02 Jul 2019	16/972085	2021-0220169		Novartis AG
Topical Ocular Delivery Devices And Methods For Using The Same	United States Of America	03 Jul 2018	62/693818			Novartis AG
Fluid Delivery System	United States Of America	05 Apr 2018	62/653446			Novartis AG
Piezoelectric Clamping Dispenser With Replaceable Ampoule	United States Of America	15 Jun 2017	62/520270			Novartis AG
Piezoelectric Clamping Dispenser With Replaceable Ampoule (II)	United States Of America	21 Jun 2017	62/523071			Novartis AG
	United States Of America	03 May 2023	18/311673			Novartis AG

PATENT

REEL: 065531 FRAME: 0617

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
	United States Of America	06 Mar 2020	16/811879	2020-0281768		Novartis AG
	United States Of America	06 Mar 2019	62/814773			Novartis AG


	United States Of America	18 Jul 2017	62/534083			Novartis AG
Topical Ocular Cholinergic Agent Micro-dose Delivery Methods And Devices For Use In The Same	United States Of America	06 Mar 2019	62/814764			Novartis AG

Electromagnetic Dispenser of Fluid to Ocular Surface	United States Of America	18 Dec 2020	17/127584			Novartis AG
Electromagnetic Dispenser of Fluid to Ocular Surface	United States Of America	20 Dec 2019	62/951903			Novartis AG
Electromagnetic Dispenser of Fluid to Ocular Surface	United States Of America	07 Aug 2020	63/049582			Novartis AG

PATENT

REEL: 065531 FRAME: 0618

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
Smart Topical Ocular Delivery Methods And Devices For Use In The Same	United States Of America	10 Oct 2019	62/913498			Novartis AG
	United States Of America	11 Dec 2020	17/096348			Novartis AG
	United States Of America	12 Nov 2019	62/934225			Novartis AG
Multi-Dose Ocular Fluid Delivery System	United States Of America	17 Apr 2020	63/011800			Novartis AG
Multi-Dose Ocular Fluid Delivery System	United States Of America	07 Jul 2020	63/049110			Novartis AG




	United States Of America	25 Oct 2021	17/509383			Novartis AG
	United States Of America	11 Mar 2022	17/692991			Novartis AG
	United States Of America	16 Apr 2021	17/233105			Novartis AG
	United States Of America	17 Apr 2020	63/011808			Novartis AG

PATENT

REEL: 065531 FRAME: 0619

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
Hydrodynamically Actuated Preservative Free Dispensing System Having a Collapsible Fluid Chamber	United States Of America	16 Apr 2021	17/233135			Novartis AG
	United States Of America	26 Mar 2021	63/166754			Novartis AG



Hydrodynamically Actuated Fluid Dispensing Apparatus with Replaceable Reservoir	United States Of America	11 Mar 2021	63/159830			Novartis AG
Hydrodynamically Actuated Preservative Free Dispensing System having a Magnetically Attached Reservoir Assembly	United States Of America	18 Jun 2021	63/212545			Novartis AG
Membrane Actuated Hydrodynamic Dispensing System	United States Of America	25 Mar 2022	63/323859			Novartis AG



Vented Multi-Dose Ocular Fluid Delivery System having an Anti-Clog System	United States Of America	02 May 2022	63/337372			Novartis AG
---	--------------------------	-------------	-----------	--	--	-------------




Fractionated Drug Delivery of Biological or Chemical Agents	United States Of America	07 Mar 2022	63/317381			Novartis AG
---	--------------------------	-------------	-----------	--	--	-------------

PATENT

REEL: 065531 FRAME: 0620

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
Fractionated Drug Delivery of Biological or Chemical Agents	United States Of America	17 Mar 2022	63/321028			Novartis AG
Liquid Dispensing Systems And Methods	United States Of America	12 May 2023	63/501790			Novartis AG



PATENT

REEL: 065531 FRAME: 0621


Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
-------	---------	-------------	---------------	--------------------	--------------	-------------



Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
-------	---------	-------------	---------------	--------------------	--------------	-------------


PATENT

REEL: 065531 FRAME: 0629

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
-------	---------	-------------	---------------	--------------------	--------------	-------------




Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
-------	---------	-------------	---------------	--------------------	--------------	-------------



Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

Title	Country	Filing Date	Filing Number	Publication Number	Grant Number	Legal Owner
[REDACTED]						

PATENT

REEL: 065531 FRAME: 0639